{
  "content": "We studied the effects of amiodarone on outcomes in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. The first set of objectives compared the effects of randomized apixaban or warfarin treatment on stroke and systemic embolism, death, and bleeding events in relation to amiodarone use at the time of randomization. In the second set of objectives, we compared the rates of cardiovascular death and noncardiovascular death in relation to amiodarone use.\nMethods\nStudy population",
  "source": "https://www.jacc.org/doi/10.1016/j.jacc.2014.07.967",
  "chunk_id": "f8aa2714-ce61-45d3-b20f-da5ac627b2df",
  "similarity_score": 0.3066974878311157,
  "query": "atrial fibrillation mortality outcomes cardiovascular events stroke prevention amiodarone beta-blockers hazard ratio",
  "rank": 37,
  "title": "Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial",
  "authors": "Greg Flaker, Renato D. Lopes, Elaine Hylek, Daniel M. Wojdyla, Laine Thomas, Sana M. Al-Khatib, Renee M. Sullivan, Stefan H. Hohnloser, David Garcia, Michael Hanna, John Amerena, Veli-Pekka Harjola, Paul Dorian, Alvaro Avezum, Matyas Keltai, Lars Wallentin, Christopher B. Granger",
  "year": "2014",
  "journal": "JACC",
  "reference": "Flaker, G., Lopes, R. D., Hylek, E., Wojdyla, D. M., Thomas, L., Al-Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D., Hanna, M., Amerena, J., Harjola, V.-P., Dorian, P., Avezum, A., Keltai, M., Wallentin, L., & Granger, C. B. (2014). Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. JACC, 64(15), 556-575.",
  "doi": "Not available",
  "chunk_index": 12,
  "total_chunks": 111,
  "retrieved_at": "2025-07-24T21:57:59.084710"
}